Stockreport

Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Fo...

NanoViricides, Inc.  (NNVC) 
NASDAQ:AMEX Investor Relations: nanoviricides.com/investorinfo.html
PDF effective antiviral therapies based on a novel nanomedicines technology, reported today that the healthy subjects part of the Phase 1a/1b Clinical Trial of NV-CoV-2 was [Read more]